Abstract

Backgrounds: Early B-cell factor 1 (EBF1), originally identified as a critical transcription factor modulating the development and differentiation of B lymphocytes, has recently attracted significant interest owing to its diverse functional characteristics and regulatory mechanisms in solid tumors. Although current evidence suggests a potential connection between EBF1 and oncogenic developments, its exact role in the progression of prostate cancer (PCa) is unclear. This study sought to investigate its biological roles and regulatory mechanisms in human PCa. Methods: Bioinformatic analyses were performed utilizing Tumor Immune Estimation Resource (TIMER) 2.0, Gene Expression Profiling Interactive Analysis (GEPIA), and Gene Expression Omnibus (GEO) databases, along with quantitative polymerase chain reaction (qPCR) assays and immunostaining on clinically available PCa and normal prostate tissues, to investigate the expression profile and clinical significance of EBF1. The manipulation of EBF1 expression through lentivirus was conducted to explore the impact of both knockdown and overexpression of EBF1 on the malignant behaviors of PCa cells in vitro, as well as in a xenograft mouse model. Ultimately, various molecular biomedical techniques were employed to clarify the possible transcriptional regulation of inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) by EBF1. Results: Bioinformatic analyses revealed that reduced EBF1 expression exhibited a robust prognostic association with PCa progression.